The latentiation process in drug design.

被引:0
|
作者
Chin, CM
Ferreira, EI
机构
[1] UNESP, Fac Ciencias Farmaceut, Dept Farm & Med, BR-14801902 Araraquara, SP, Brazil
[2] USP, Fac Ciencias Farmaceut, Dept Farm, BR-05389970 Sao Paulo, Brazil
来源
QUIMICA NOVA | 1999年 / 22卷 / 01期
关键词
latentiation; molecular modification; prodrug design; drug design;
D O I
暂无
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Short review about the main aspects of prodrug design, as its objectives, applicability and importance, showing the new trends in the research for selective latent forms, namely targeted drugs.
引用
收藏
页码:75 / 84
页数:10
相关论文
共 50 条
  • [1] DRUG LATENTIATION
    HARPER, NJ
    [J]. JOURNAL OF MEDICINAL & PHARMACEUTICAL CHEMISTRY, 1959, 1 (05): : 467 - 500
  • [2] Chirality and drug design.
    Anderson, PS
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1997, 213 : 285 - MEDI
  • [3] DESIGN. THE MANUFACTURING PROCESS
    不详
    [J]. CONNAISSANCE DES ARTS, 2013, (715): : 134 - 134
  • [4] DRUG LATENTIATION OF TERBUTALINE
    KRISTOFFERSSON, J
    SVENSSON, LA
    TEGNER, K
    [J]. ACTA PHARMACEUTICA SUECICA, 1974, 11 (05): : 427 - 438
  • [5] Issues of solvation in drug design.
    Stouch, TR
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2002, 224 : U474 - U474
  • [6] Molecular connectivity and drug design.
    Galvez, J
    Garcia-Domenech, R
    de Julián-Ortiz, JV
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2000, 220 : U284 - U284
  • [7] The importance of metabolism in drug design.
    Pereira, Darcio Gomes
    [J]. QUIMICA NOVA, 2007, 30 (01): : 171 - 177
  • [8] Bioavailability consideration in drug design.
    Baldwin, JJ
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2000, 219 : U459 - U459
  • [9] DRUG LATENTIATION IN CANCER CHEMOTHERAPY
    WORKMAN, P
    DOUBLE, JA
    [J]. BIOMEDICINE, 1978, 28 (05): : 255 - 262
  • [10] Computer-aided drug design.
    Holloway, MK
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2004, 228 : U544 - U544